2017
DOI: 10.2174/9781681084879117040007
|View full text |Cite
|
Sign up to set email alerts
|

Monoclonal Antibodies - Addressing the Challenges on the Manufacturing Processing of an Advanced Class of Therapeutic Agents

Abstract: Monoclonal antibodies (mAbs) were firstly described by Köhler and Milstein in 1975, and their potential as powerful therapeutic agents recognized in the following years. Currently, the US Food and Drug Administration (FDA) has already approved 56 monoclonal antibodies for the treatment of several diseases, including cancer (e.g. breast cancer, leukemia and prostate cancer), auto-immune disorders (rheumatoid arthritis and Crohn's disease), asthma, and cardiovascular and infectious diseases. Despite their advant… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
references
References 182 publications
(277 reference statements)
0
0
0
Order By: Relevance